We are live on ! Find out more
GD

Grandfield & Dodd Portfolio holdings

AUM $1.91B
1-Year Est. Return 31.61%
This Fund
S&P 500
This Quarter Est. Return
+0.79%
1 Year Est. Return
+31.61%
3 Year Est. Return
+70.8%
5 Year Est. Return
+92.39%
10 Year Est. Return
+369.61%
AUM
$1.02B
AUM Growth
+$4.67M
Cap. Flow
+$2.09M
Cap. Flow %
0.21%
Top 10 Hldgs %
30.27%
Holding
183
New
2
Increased
49
Reduced
56
Closed
6

Top Buys

Rank Stock Value
1
BLKB icon
Blackbaud
BLKB
+$880K
2
WLY icon
John Wiley & Sons Class A
WLY
+$642K
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$597K
4
USB icon
US Bancorp
USB
+$563K
5
CVX icon
Chevron
CVX
+$444K

Top Sells

Rank Stock Value
1
DOX icon
Amdocs
DOX
+$566K
2
SYK icon
Stryker
SYK
+$501K
3
MSFT icon
Microsoft
MSFT
+$415K
4
ARRY
Array Biopharma Inc
ARRY
+$369K
5
GS icon
Goldman Sachs
GS
+$321K

Sector Composition

Rank Sector Weight
1 Technology 26.47%
2 Healthcare 17.23%
3 Consumer Staples 12.12%
4 Financials 11.97%
5 Industrials 10.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PM icon
101
Philip Morris
PM
$303B
$813K 0.08%
10,708
+147
+1% +$11.6K
ALC icon
102
Alcon
ALC
$32.8B
$797K 0.08%
13,668
-5,148
-27% -$309K
GLD icon
103
SPDR Gold Trust
GLD
$145B
$795K 0.08%
5,727
– –
V icon
104
Visa
V
$701B
$786K 0.08%
4,570
-30
-0.7% -$5.34K
VV icon
105
Vanguard Morningstar Large-Cap ETF
VV
$53.7B
$774K 0.08%
5,680
– –
XRAY icon
106
Dentsply Sirona
XRAY
$1.96B
$773K 0.08%
14,502
-2,600
-15% -$140K
BMY icon
107
Bristol-Myers Squibb
BMY
$130B
$772K 0.08%
15,224
-150
-1% -$7.05K
DD icon
108
DuPont de Nemours
DD
$17.3B
$769K 0.08%
8,594
-69
-0.8% -$6.08K
BA icon
109
Boeing
BA
$166B
$734K 0.07%
1,928
– –
INCY icon
110
Incyte
INCY
$24.7B
$723K 0.07%
9,740
+845
+9% +$68.3K
FISV
111
Fiserv Inc
FISV
$26.6B
$684K 0.07%
6,601
+105
+2% +$10.7K
VEU icon
112
Vanguard FTSE All-World ex-US ETF
VEU
$69.1B
$682K 0.07%
13,670
– –
SCHW
113
Charles Schwab
SCHW
$186B
$673K 0.07%
16,092
– –
J icon
114
Jacobs Solutions
J
$17B
$666K 0.07%
8,798
– –
NEE icon
115
NextEra Energy
NEE
$169B
$663K 0.07%
11,380
– –
RDS.A
116
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$653K 0.06%
11,098
– –
LLY icon
117
Eli Lilly
LLY
$1.01T
$646K 0.06%
5,775
-150
-3% -$16.7K
CSX icon
118
CSX Corp
CSX
$90.1B
$630K 0.06%
27,300
– –
MCD icon
119
McDonald's
MCD
$179B
$620K 0.06%
2,887
– –
ED icon
120
Consolidated Edison
ED
$38.9B
$581K 0.06%
6,146
– –
BMRN icon
121
BioMarin Pharmaceuticals
BMRN
$12.5B
$570K 0.06%
8,463
+930
+12% +$71.6K
FUL icon
122
H.B. Fuller
FUL
$2.74B
$563K 0.06%
12,094
– –
AMZN icon
123
Amazon
AMZN
$2.68T
$559K 0.06%
6,440
-160
-2% -$14.8K
TGT icon
124
Target
TGT
$70.1B
$558K 0.05%
5,219
– –
OMC icon
125
Omnicom Group
OMC
$21.9B
$557K 0.05%
7,111
– –
3 4
5
6 7

Similar funds

CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
R
Rebalance Palo Alto, California $1.91B AUM 16.23% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.9B AUM 36.41% 1-Year Est. Return
DC
Dendur Capital New York $1.9B AUM 46.69% 1-Year Est. Return
LWMT
Legacy Wealth Management (Tennessee) Memphis, Tennessee $1.91B AUM 17.42% 1-Year Est. Return
FVWA
Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return
PP
PDT Partners New York $1.9B AUM 71.86% 1-Year Est. Return
RMA
Roffman Miller Associates Philadelphia, Pennsylvania $1.91B AUM 28.29% 1-Year Est. Return

Grandfield & Dodd's Q3 2019 Portfolio in Review

As of Q3 2019, Grandfield & Dodd held 183 positions worth $1.02B, up 0.46% from $1.01B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Trading was light in Q3 2019: portfolio turnover was 4.4%. Grandfield & Dodd opened 2 new positions and exited 6, leaving the 183-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 26% a quarter earlier, followed by Healthcare and Consumer Staples.

  • Grandfield & Dodd's largest Q3 2019 buy was iShares Russell 1000 Growth ETF: 5,832 shares worth $233K.
  • Grandfield & Dodd added most to Blackbaud in Q3 2019, an estimated $880K increase.
  • Grandfield & Dodd's biggest Q3 2019 reduction was Amdocs, cutting an estimated $566K.
  • Grandfield & Dodd fully exited Array Biopharma Inc in Q3 2019, selling an estimated $369K.
  • Grandfield & Dodd's ten largest holdings make up 30% of its $1.02B portfolio in Q3 2019.
  • Grandfield & Dodd opened 2 new positions and closed 6 in Q3 2019.
  • Grandfield & Dodd's portfolio value rose 0.46% quarter-over-quarter to $1.02B.

Based on Grandfield & Dodd's 13F filing for Q3 2019, filed 30 Oct 2019.